• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植术后新发的内部肿瘤:近年来风险增加及行为侵袭性增强?

De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?

作者信息

Benlloch Salvador, Berenguer Marina, Prieto Martín, Moreno Rosalba, San Juan Fernando, Rayón Miguel, Mir Jose, Segura Angel, Berenguer Joaquín

机构信息

Department of Hepato-Gastroenterology, Hospital Universitario La Fe, Valencia, Spain.

出版信息

Am J Transplant. 2004 Apr;4(4):596-604. doi: 10.1111/j.1600-6143.2004.00380.x.

DOI:10.1111/j.1600-6143.2004.00380.x
PMID:15023152
Abstract

The goal of the study was to determine the incidence and variables associated with post-liver transplantation (LT) de novo internal neoplasms development, excluding skin tumors and hepatocellular carcinoma. Medical records were reviewed for recipient/donor demographics, viral serology, cause of liver disease, interval from LT to tumor diagnosis, predisposing factors, immunosuppression and survival. Forty-one neoplasms (31 solid and 10 hematologic) developed in 772 recipients (5.3%) transplanted between 1991 and 2001. Time to tumor diagnosis was longer in patients transplanted before 1995 than in those transplanted afterwards (58 vs. 22 months; p<0.05). Hematologic neoplasms (HN) appeared earlier than solid (2 vs. 21 months; p<0.001), were more prevalent in those transplanted after 1995 than before (32% vs. 12.5%), and had lower survival than solid (2 vs. 21 months, p<0.001). While HCV was the most frequent indication in HN (70%), alcohol was that of solid tumors (71%). Overall, risk factors for de novo neoplasms included alcohol and immunosuppression (p<0.01). In patients undergoing LT in recent years, there is a higher incidence of HN with de novo internal neoplasms developing at earlier time-points than in those transplanted years ago. Risk factors for tumor development include alcohol, HCV and possibly strong immunosuppression.

摘要

本研究的目的是确定肝移植(LT)后新发内脏肿瘤(不包括皮肤肿瘤和肝细胞癌)的发病率及相关变量。回顾了受者/供者的人口统计学资料、病毒血清学、肝脏疾病病因、从肝移植到肿瘤诊断的时间间隔、易感因素、免疫抑制情况及生存情况。1991年至2001年间接受移植的772例受者中发生了41例肿瘤(31例实体瘤和10例血液系统肿瘤)(5.3%)。1995年前接受移植的患者肿瘤诊断时间比之后接受移植的患者更长(58个月对22个月;p<0.05)。血液系统肿瘤(HN)比实体瘤出现得更早(2个月对21个月;p<0.001),在1995年后接受移植的患者中比之前更常见(32%对12.5%),且生存率低于实体瘤(2个月对21个月,p<0.001)。虽然丙型肝炎病毒(HCV)是血液系统肿瘤最常见的病因(70%),但酒精是实体瘤的最常见病因(71%)。总体而言,新发肿瘤的危险因素包括酒精和免疫抑制(p<0.01)。近年来接受肝移植的患者中,血液系统肿瘤的发病率更高,新发内脏肿瘤在更早的时间点出现,比多年前接受移植的患者情况更严重。肿瘤发生的危险因素包括酒精、HCV以及可能存在的强效免疫抑制。

相似文献

1
De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?肝移植术后新发的内部肿瘤:近年来风险增加及行为侵袭性增强?
Am J Transplant. 2004 Apr;4(4):596-604. doi: 10.1111/j.1600-6143.2004.00380.x.
2
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.肝移植患者中基于移植前病因的移植后恶性肿瘤差异风险证据。
Liver Transpl. 2002 May;8(5):482-7. doi: 10.1053/jlts.2002.32977.
3
Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.肝移植受者发生非淋巴样实体器官肿瘤的风险并未增加。
Cancer. 1998 Sep 15;83(6):1237-43.
4
malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.肝移植后的恶性肿瘤:免疫抑制的影响——个人数据和文献回顾。
World J Gastroenterol. 2019 Sep 21;25(35):5356-5375. doi: 10.3748/wjg.v25.i35.5356.
5
Characteristics of de novo cancer in liver transplant recipients.肝移植受者新发癌症的特征。
APMIS. 2023 Apr;131(4):135-141. doi: 10.1111/apm.13296. Epub 2023 Feb 14.
6
Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation.肝移植后与抗谷胱甘肽S-转移酶T1抗体相关的新发自身免疫性肝炎的危险因素。
Liver Transpl. 2009 May;15(5):530-9. doi: 10.1002/lt.21721.
7
Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.从基于钙调神经磷酸酶抑制剂的免疫抑制转换为霉酚酸酯单药治疗可降低肝移植后新发恶性肿瘤的风险。
Ann Transplant. 2017 Mar 17;22:141-147. doi: 10.12659/aot.901556.
8
De novo tumors after liver transplantation: a single-institution experience.肝移植后的新发肿瘤:单中心经验
Liver Transpl. 2002 Mar;8(3):285-91. doi: 10.1053/jlts.2002.29350.
9
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.肝移植受者接受环孢素治疗后早期新发癌症的发病率增加:与 C2 监测和受者年龄有关。
Liver Transpl. 2010 Jul;16(7):837-46. doi: 10.1002/lt.22064.
10
Neoplastic disease after liver transplantation: Focus on de novo neoplasms.肝移植后的肿瘤性疾病:聚焦于新发肿瘤。
World J Gastroenterol. 2015 Aug 7;21(29):8753-68. doi: 10.3748/wjg.v21.i29.8753.

引用本文的文献

1
Incidence, screening, and management of malignancies in liver transplant patients: A review.肝移植患者恶性肿瘤的发病率、筛查与管理:综述
World J Transplant. 2025 Sep 18;15(3):101046. doi: 10.5500/wjt.v15.i3.101046.
2
Reconstructive Surgery of the Head and Neck in Organ Transplant Recipients: A Case Report and a Review of the Literature.器官移植受者的头颈部重建手术:一例病例报告及文献综述
J Clin Med. 2024 Aug 14;13(16):4790. doi: 10.3390/jcm13164790.
3
Lung cancer incidences after liver transplantation: A systematic review and meta-analysis.
肝移植后肺癌的发病率:系统评价和荟萃分析。
Cancer Med. 2023 Aug;12(15):16119-16128. doi: 10.1002/cam4.6265. Epub 2023 Jun 23.
4
Main factors influencing long-term outcomes of liver transplantation in 2022.2022年影响肝移植长期预后的主要因素。
World J Hepatol. 2023 Mar 27;15(3):321-352. doi: 10.4254/wjh.v15.i3.321.
5
Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.肝移植后他克莫司的累积暴露量与癌症发生率
Am J Transplant. 2022 Jun;22(6):1671-1682. doi: 10.1111/ajt.17021. Epub 2022 Mar 31.
6
Current Status of Malignant Tumors after Organ Transplantation.器官移植后恶性肿瘤的现状。
Biomed Res Int. 2022 Feb 18;2022:5852451. doi: 10.1155/2022/5852451. eCollection 2022.
7
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.接受移植前直接抗病毒(DAA)治疗的丙型肝炎病毒(HCV)肝移植受者肝细胞癌的复发情况
Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.
8
Post-transplant malignancies in alcoholic liver disease.酒精性肝病中的移植后恶性肿瘤
Transl Gastroenterol Hepatol. 2020 Apr 5;5:30. doi: 10.21037/tgh.2019.11.18. eCollection 2020.
9
Alcohol use disorder and liver transplant: new perspectives and critical issues.酒精使用障碍与肝移植:新视角和关键问题。
Korean J Intern Med. 2020 Jul;35(4):797-810. doi: 10.3904/kjim.2019.409. Epub 2020 Apr 3.
10
malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.肝移植后的恶性肿瘤:免疫抑制的影响——个人数据和文献回顾。
World J Gastroenterol. 2019 Sep 21;25(35):5356-5375. doi: 10.3748/wjg.v25.i35.5356.